What is Histoserv?
Histoserv, Inc. operates as a premier provider of histology laboratory services, functioning as a critical node in the research and development ecosystem. By delivering high-precision histological products and analytical services, the company supports a sophisticated clientele that includes the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and leading academic research institutions. Their market position is defined by a rigorous commitment to scientific accuracy and operational excellence, enabling them to facilitate complex medical advancements and biotechnology breakthroughs. As a trusted partner to the scientific community, Histoserv bridges the gap between raw biological samples and actionable research data, maintaining a robust service portfolio that meets the stringent requirements of modern laboratory environments.
How much funding has Histoserv raised?
Histoserv has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Histoserv
PPP
Public-Private Partnership
What's next for Histoserv?
With this late-stage financing, Histoserv is well-positioned to scale its operational capacity and enhance its technological service offerings. The strategic deployment of this capital will likely focus on expanding laboratory throughput, integrating advanced digital pathology tools, and strengthening its footprint among high-tier research organizations. By leveraging its established reputation with federal agencies and academic institutions, the company is poised to capture additional market share in the histology services industry. Future growth initiatives will likely prioritize the optimization of supply chain logistics and the potential acquisition of specialized diagnostic technologies to maintain its competitive edge in the evolving biotechnology landscape.
See full Histoserv company page
